BIOMAT Database Logo BIOMAT Database Logo

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. 1998

P Mathurin, and J Moussalli, and J F Cadranel, and V Thibault, and F Charlotte, and P Dumouchel, and A Cazier, and J M Huraux, and B Devergie, and M Vidaud, and P Opolon, and T Poynard
Service d'HépatoGastroentérologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

In hepatitis C virus (HCV) patients with persistently normal alanine transaminase (ALT), the progression rate of fibrosis is unknown. The aims of this study were: 1) to compare HCV patients with normal ALT (group I) with HCV patients with elevated ALT (group II) matched on independent factors associated with fibrosis; and 2) to assess the progression rate of fibrosis. One hundred two HCV patients were included in each group. Histological lesions were staged using the METAVIR score. We defined fibrosis progression per year as the ratio of the fibrosis stage in METAVIR units to the duration of infection. In group I, ALT values were normal, and lower than in group II (25 vs. 127 IU/L; P < .0001). HCV RNA was present less frequently in group I (66% vs. 97%; P < .0001). There were no significant differences for viremia and genotypes. Histological activities were lower in group I (0.6 vs. 1.38; P < .0001). The stage of fibrosis was lower in group I (0.95 vs. 1.8; P < .001). The median progression rate of fibrosis was lower in group I (0.05 vs. 0.13; P < .001). In group I, after exclusion of negative HCV-RNA patients, the median progression rate of positives remained lower (0.05 vs. 0.13; P < .001). In group I, all cirrhotic patients (n = 3) were heavy drinkers. HCV patients with normal ALT showed weaker histological activity and lower fibrosis scores, and the progression rate of fibrosis was twice as slow as in HCV patients with elevated ALT. In these patients, severe fibrosis was associated with high alcohol consumption.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

P Mathurin, and J Moussalli, and J F Cadranel, and V Thibault, and F Charlotte, and P Dumouchel, and A Cazier, and J M Huraux, and B Devergie, and M Vidaud, and P Opolon, and T Poynard
Chronic hepatitis C in patients with persistently normal alanine transaminase levels.
May 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,
P Mathurin, and J Moussalli, and J F Cadranel, and V Thibault, and F Charlotte, and P Dumouchel, and A Cazier, and J M Huraux, and B Devergie, and M Vidaud, and P Opolon, and T Poynard
Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA.
November 2001, Hepatology (Baltimore, Md.),
P Mathurin, and J Moussalli, and J F Cadranel, and V Thibault, and F Charlotte, and P Dumouchel, and A Cazier, and J M Huraux, and B Devergie, and M Vidaud, and P Opolon, and T Poynard
Liver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levels.
January 2006, Journal of acquired immune deficiency syndromes (1999),
P Mathurin, and J Moussalli, and J F Cadranel, and V Thibault, and F Charlotte, and P Dumouchel, and A Cazier, and J M Huraux, and B Devergie, and M Vidaud, and P Opolon, and T Poynard
Disease progression in Chinese chronic hepatitis C patients with persistently normal alanine aminotransaminase levels.
June 2007, Alimentary pharmacology & therapeutics,
P Mathurin, and J Moussalli, and J F Cadranel, and V Thibault, and F Charlotte, and P Dumouchel, and A Cazier, and J M Huraux, and B Devergie, and M Vidaud, and P Opolon, and T Poynard
Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels.
December 1997, Hepatology (Baltimore, Md.),
P Mathurin, and J Moussalli, and J F Cadranel, and V Thibault, and F Charlotte, and P Dumouchel, and A Cazier, and J M Huraux, and B Devergie, and M Vidaud, and P Opolon, and T Poynard
Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States.
November 1999, Hepatology (Baltimore, Md.),
P Mathurin, and J Moussalli, and J F Cadranel, and V Thibault, and F Charlotte, and P Dumouchel, and A Cazier, and J M Huraux, and B Devergie, and M Vidaud, and P Opolon, and T Poynard
Persistently normal alanine transaminase levels in chronic C hepatitis: what does it tell us?
January 2001, Hepato-gastroenterology,
P Mathurin, and J Moussalli, and J F Cadranel, and V Thibault, and F Charlotte, and P Dumouchel, and A Cazier, and J M Huraux, and B Devergie, and M Vidaud, and P Opolon, and T Poynard
A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase.
April 2003, Journal of hepatology,
P Mathurin, and J Moussalli, and J F Cadranel, and V Thibault, and F Charlotte, and P Dumouchel, and A Cazier, and J M Huraux, and B Devergie, and M Vidaud, and P Opolon, and T Poynard
Clinical features of hepatitis C virus carriers with persistently normal alanine aminotransferase levels.
February 2012, Hepatitis monthly,
P Mathurin, and J Moussalli, and J F Cadranel, and V Thibault, and F Charlotte, and P Dumouchel, and A Cazier, and J M Huraux, and B Devergie, and M Vidaud, and P Opolon, and T Poynard
IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase.
November 2013, World journal of hepatology,
Copied contents to your clipboard!